Prime Medicine, Inc. (NASDAQ:PRME) Stock Has Consensus Price Target of $7.86

Shares of Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) have been given an average rating of “Moderate Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $7.86.

A number of analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prime Medicine in a report on Monday, August 31st. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Prime Medicine in a research note on Monday. Jefferies Financial Group restated a “market outperform” rating on shares of Prime Medicine in a report on Monday, September 28th. Citigroup reaffirmed a “market outperform” rating on shares of Prime Medicine in a research report on Friday, September 25th. Finally, BMO Capital Markets initiated coverage on Prime Medicine in a research report on Tuesday, August 18th. They set an “outperform” rating and a $9.00 price target for the company.

View Our Latest Analysis on PRME

More Prime Medicine News

Here’s some of the latest news about PRME:

  • Positive Sentiment: HC Wainwright improved its loss forecasts, including Q4 2026 EPS to ($0.26) from ($0.32) and full-year 2026 EPS to ($0.99) from ($1.11). It also modestly raised estimates for 2027–2030, indicating expectations for smaller losses than previously projected. Prime Medicine Stock Rating Reaffirmed as Buy by HC Wainwright
  • Positive Sentiment: The firm reiterated its Buy rating and $8 target, well above the $3.84 reference price in the supplied background, a bullish analyst view that could bolster the stock. HC Wainwright stock recommendations

Prime Medicine Stock Performance

NASDAQ:PRME opened at $3.84 on Wednesday. The firm has a market cap of $698.57 million, a PE ratio of -4.00 and a beta of 2.14. The business has a 50 day moving average price of $3.71 and a 200-day moving average price of $3.51. Prime Medicine has a fifty-two week low of $2.67 and a fifty-two week high of $5.91.

Prime Medicine (NASDAQ:PRME – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. The business had revenue of $4.21 million for the quarter. Research analysts predict that Prime Medicine will post -0.97 EPS for the current year.

Hedge Funds Weigh In On Prime Medicine

Hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Prime Medicine in the third quarter worth about $28,000. Royal Bank of Canada grew its holdings in shares of Prime Medicine by 89.3% during the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock worth $32,000 after acquiring an additional 4,365 shares during the period. Wealthfront Advisers LLC purchased a new position in shares of Prime Medicine during the 1st quarter worth approximately $36,000. Kingsview Wealth Management LLC purchased a new position in shares of Prime Medicine during the 2nd quarter worth approximately $37,000. Finally, Sequoia Financial Advisors LLC bought a new position in shares of Prime Medicine in the 1st quarter worth approximately $41,000. 70.37% of the stock is owned by hedge funds and other institutional investors.

Prime Medicine Company Profile

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

Recommended Stories

Analyst Recommendations for Prime Medicine (NASDAQ:PRME)

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.